Boehringer Ingelheim Humira biosimilar available at low wholesale acquisition cost

Adalimumab-adbm injection is now available at a low wholesale acquisition cost, Boehringer Ingelheim announced in a company press release.
Adalimumab-adbm, Boehringer Ingelheim’s interchangeable biosimilar to Humira (adalimumab) for the treatment of multiple chronic inflammatory diseases, is set to be priced at an 81% discount to Humira.
The biosimilar is also available under the brand name Cyltezo. Launched in July, Cyltezo is priced at a 5% discount to Humira.
“We understand that finding affordable medications is a persistent challenge for many, which is why we strive to ensure our

Adalimumab-adbm injection is now available at a low wholesale acquisition cost, Boehringer Ingelheim announced in a company press release.
Adalimumab-adbm, Boehringer Ingelheim’s interchangeable biosimilar to Humira (adalimumab) for the treatment of multiple chronic inflammatory diseases, is set to be priced at an 81% discount to Humira.
The biosimilar is also available under the brand name Cyltezo. Launched in July, Cyltezo is priced at a 5% discount to Humira.
“We understand that finding affordable medications is a persistent challenge for many, which is why we strive to ensure our